Key Takeaways
- BPGbio's biology-first approach to AI drug discovery has yielded promising clinical results in hard-to-treat cancers.
- Targeting E2 enzymes rather than E3 ligases could be a breakthrough approach for protein degradation therapies.
- BPGbio's real-time use of clinical data and causal AI models enables more precise patient selection and optimized trial design.
In an industry enamored with artificial intelligence breakthroughs, BPGbio stands apart with a refreshingly pragmatic approach. “At the end of the day, when someone’s lying in a hospital bed, they don’t give a sh*t about the algorithms. They want a drug to save them,” CEO Niven Narain stated bluntly in an interview with In Vivo
Formed in January 2023 through an asset transaction from Berg Health (an AI platform company Narain co-founded along with and a real estate investor in 2009), BPGbio has assembled what Narain described as “the industry’s first industrial AI
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?